INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 432m ago
HOUSE PTR31m ago
SEC 13F31m ago
ROBINHOOD CHAIN31m ago
HOUSE PTR/PurchaseVerified data

Jared Moskowitz bought GILD

Dependent child · GILEAD SCIENCES, INC. · Gilead Sciences, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
May 6, 2026
Disclosed
Jun 19, 2026
Disclosure timeline44 days from execution to publication · legal deadline 45 days
May 6 executedJun 19, 2026 disclosed

GILD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
28/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing+4 / 15

    Disclosed 44 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GILD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$469K
    3,000 sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    24
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$117K
    768 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    5
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$38K
    263 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    8
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$195K
    1,347 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$41K
    285 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    13
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    11
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$613K
    4,230 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M—
    4,665 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M$21K
    335 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    1
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$3,805
    26 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M$1,754
    26 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20034749

    Timestamps

    Event (reported)
    May 6, 2026
    Published
    Jun 19, 2026
    Ingested by INSIDER
    Nov 5, 00:34 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Jared Moskowitz
    Role
    Dependent childAs filed: “DC”
    Transaction
    PurchaseAs filed: “P”
    Asset
    Gilead Sciences, Inc. - Common Stock
    Ticker
    GILD
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    May 6, 2026
    Notification date (reported)
    May 31, 2026
    Days from execution to publication
    44

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Jared Moskowitz reported a purchase of Gilead Sciences, Inc. - Common Stock (owner: dependent child). Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Dependent child
    Jared Moskowitzbioguide:M001217
    Issuer
    GILEAD SCIENCES, INC.cik:0000882095

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.